Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 26, 2001

View Archived Issues

Phase II trial of TH-9507 in type 2 diabetes cleared by FDA

NeuroSearch offers interim progress report

Hemosol given green light to proceed with Hemolink clinical program

FDA approval for Genesis IPG Spinal Cord Stimulator system

Rebetol receives Japanese approval for use in combination with Intron A for hepatitis C

AASLD news: Gilead's adefovir dipivoxil improves liver function and reduces viral load in HBV

Design and biological activity of new camptothecin glycoconjugates described by Bayer

Accelerated progress marks Q3 at Xenova

Primary endpoint of large tifacogin trial in sepsis patients not met according to Chiron

Specific activation of amygdala neurons and brain penetration demonstrated for secretin

Interim report shows British Biotech continues to make good progress

Preclinical data support use of dexanabinol in neuroinflammatory disorders

Antimalarial prodrugs in development at Jacobus

Successful human somatic cell nuclear transfer and parthenogenesis

Second conference on neuroimmunophilins held during SFN meeting

Abbott continues to pursue highly selective ETA receptor antagonists

Introduction of SynX's diagnostic aid for Alzheimer's disease

M-55113: an anticoagulant factor Xa inhibitor designed at Mochida

New product significantly reduces the risk of AMD

Abbott's acquisition of Vysis clears antitrust review

Specific inhibition of MMP-2 binding to alphavbeta3 integrin for inhibiting angiogenesis

Antitumor sulfonamide derivatives reported in recent patent by Sankyo

Protein tyrosine kinase inhibitors from AHP exert antitumor activity in vitro

Lactam inhibitors of Abeta peptide and their use in Alzheimer's disease and related disorders

ADIR prepares inhibitors of monoamine reuptake for CNS disorders

New gastric antisecretory agents designed by Byk Gulden

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...